πππMirxes-B
$MIRXES-B(02629)$ is a Singapore based biotechnology company that uses cutting edge microRNA technology to develop diagnostic solutions for early detection of diseases.
Their tests like the GASTROClear blood based panel are designed to screen for cancers as well as cardiovascular, metabolic and infectious diseases.
The success of Mirxes-B IPO in Hong Kong is due to overwhelming investor enthusiasm and robust market conditions for high growth biotech stocks. The IPO was oversubscribed too.
It is exciting times ahead for Hong Kong IPO markets.
@Tiger_comments @TigerStars @Tiger_SG @CaptainTiger @TigerClub
Saint Bella Surging 40%: Next Big Thing is IFBH?
Today, Zhou Liu Fu and Saint Bella rises on debut day.
Which one do you have more confidence in?
Can we buy after the rally?
Will you trade IFBH, coconut water product?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments